Improved Long-term Survival with Contralateral Prophylactic Mastectomy among Young Women

  • Published : 2014.02.01


Background: Despite mixed survival data, the utilization of contralateral prophylactic mastectomy (CPM) for the prevention of a contralateral breast cancer (CBC) has increased significantly over the last 15 years, especially among women less than 40. We set out to look at our own experience with CPM, focusing on outcomes in women less than 40, the sub-population with the highest cumulative lifetime risk of developing CBC. With an extended follow-up, we hoped to demonstrate differences in the long-term disease free survival (DFS) and overall survival (OS) among groups who underwent the procedure (CPM) versus those that did not (NCPM). Materials and Methods: We performed a retrospective review of all breast cancer patients less than age 40 diagnosed at Mount Sinai Medical Center between January 1, 1980 and December 31, 2010 (n=481). Among these patients, 42 were identified as having undergone CPM, while 195 were confirmed as being CPM-free during the observation period. A univariate and multivariate analyses were performed. Results: The CPM group had a significantly higher percentage of patients who were diagnosed between 2000 and 2010 (95.2% vs 40%, p=0.0001). The CPM group had significantly smaller tumors (0-2cm.: 41.7% vs 24.8%, p=0.04). Among the entire group of patients, the overall five- and 10-year DFS were 81.3% and 73.3%, respectively. CPM was significantly associated [HR 2.35 (1.02, 5.41); p=0.046] with 10-year OS, although a similar effect was not observed for five-year OS. Conclusions: We found that CPM has increased dramatically over the last 15 years, especially among white women with locally advanced disease. In patients less than 40, who are thought to be at greatest cumulative risk of secondary breast cancer, CPM provided an OS advantage, regardless of genetics, tumor or patient characteristics, and which was only seen after 10 years of follow-up.


  1. Abbott A, Rueth N, Pappas-Varco S, et al (2011). Perceptions of contralateral breast cancer: an overestimation of risk. Ann Surg Oncol, 18, 3129-36.
  2. Adami HO, Malker B, Holmberg L, et al (1986). The relation between survival and age at diagnosis in breast cancer. N Engl J Med, 315, 559-63.
  3. Ademuyiwa FO, Groman A, Hong CC, et al (2013). Time-trends in survival in young women with breast cancer in a SEER population-based study. Breast Cancer Res Treat, 138, 241-8.
  4. Anders CK, Hsu DS, Broadwater G, et al (2008). Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression. J Clin Oncol, 26, 3324-30.
  5. Althuis MD, Brogan DD, Coates RJ, et al (2003). Breast cancers among very young premenopausal women (United States). Cancer Causes Control, 14, 151-60.
  6. Barry PN, Johnson RR, Harkenrider MM, et al (2012), Contralateral prophylactic mastectomy: clinical and pathological features from a prospective database. Am J Med Sci, 344, 452-6.
  7. Bedrosian I, Hu CY, Chang GJ (2010). Population-based study of contralateral prophylactic mastectomy and survival outcomes of breast cancer patients. J Natl Cancer Inst, 102, 401-9.
  8. Boughey JC, Hoskin TL, Degnim AC, et al (2010). Contralateral prophylactic mastectomy is associated with a survival advantage in high-risk women with a personal history of breast cancer. Ann Surg Oncol, 17, 2702-9.
  9. Brewster AM, Bedrosian I, Parker PA, et al (2012). Association between contralateral prophylactic mastectomy and breast cancer outcomes by hormone receptor status. Cancer. 118, 5637-43.
  10. Carey LA, Perou CM, Livasy CA, et al (2006) Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA, 295, 2492-02.
  11. Chung A, Huynh K, Lawrence C, Sim MS, Giuliano A (2012). Comparison of patient characteristics and outcomes of contralateral prophylactic mastectomy and unilateral total mastectomy in breast cancer patients. Ann Surg Oncol, 19, 2600-6.
  12. Chung M, Chang HR, Bland KI, et al (1996) Younger women with breast carcinoma have a poorer prognosis than older women. Cancer, 77, 97-103.<97::AID-CNCR16>3.0.CO;2-3
  13. Colleoni M, Rotmensz N, Robertson C, et al (2002) Very young women (\35 years) with operable breast cancer: features of disease at presentation. Ann Oncol, 13, 273-9.
  14. de la Rochefordiere A, Asselain B, Campana F et al (1993) Age as prognostic factor in premenopausal breast carcinoma. Lancet, 341, 1039-43.
  15. Edge SB, Byrd DR, Compton CC, et al (2010). AJCC (American Joint Committee on Cancer). Cancer Staging Manual, 7th edition, Springer-Verlag. p.347.
  16. Eley JW, Hill HA, Chen VW, et al (1994). Racial differences in survival from breast cancer. Results of the National Cancer Institute Black/White Cancer Survival Study. JAMA, 272, 947-54.
  17. Frost MH, Hoskin TL, Hartmann LC, et al (2011). Contralateral prophylactic mastectomy: long-term consistency of satisfaction and adverse effects and the significance of informed, Ann Surg Oncol, 8, 3110-6.
  18. Guth U, Myrick ME, Viehl CT, et al (2012). Increasing rates of contralateral prophylactic mastectomy - a trend made in USA? Eur J Surg Oncol, 38, 296-301.
  19. Howlader N, Noone AM, Krapcho M, et al, SEER Cancer Statistics Review, 1975-2009 (Vintage 2009 Populations), National Cancer Institute. Bethesda, MD,, based on November 2011 SEER data submission, posted to the SEER web site, 2012.
  20. Jones NB, Wilson J, Kotur L, et al (2009). Contralateral prophylactic mastectomy for unilateral breast cancer: an increasing trend at a single institution. Ann Surg Oncol, 16, 2691-6.
  21. Katipamula R, Degnim AC, Hoskin T, et al (2009). Trends in mastectomy rates at the Mayo Clinic Rochester: effect of surgical year and preoperative magnetic resonance imaging. J Clin Oncol, 27, 4082-8.
  22. Katz SJ, Morrow M (2013). Contralateral prophylactic mastectomy for breast cancer: addressing peace of mind. JAMA, 310, 793-4.
  23. Khan SA (2011). Contralateral prophylactic mastectomy: what do we know and what do our patients know? J Clin Oncol, 29, 2132-5.
  24. King TA, Sakr R, Patil S, et al (2011). Clinical management factors contribute to the decision for contralateral prophylactic mastectomy. J Clin Oncol, 29, 2158-64.
  25. Kurian AW, Fish K, Shema SJ, et al (2010) Lifetime risks of specific breast cancer subtypes among women in four racial/ethnic groups. Breast Cancer Res, 12, 99.
  26. Loi S, Haibe-Kains B, Desmedt C, et al (2007). Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade. J Clin Oncol, 25, 1239-46.
  27. Lund MJ, Trivers KF, Porter PL, et al (2009) Race and triple negative threats to breast cancer survival: a population-based study in Atlanta, GA. Breast Cancer Res Treat, 113, 357-70.
  28. McLaughlin CC, Lillquist PP, Edge SB (2009). Surveillance of prophylactic mastectomy. Cancer, 115, 5404-12.
  29. Metcalfe KA, Lubinski J, Ghadirian P, et al (2008). Hereditary Breast Cancer Clinical Study Group. Predictors of contralateral prophylactic mastectomy in women with a BRCA1 or BRCA2 mutation: the Hereditary Breast Cancer Clinical Study Group. J Clin Oncol, 26, 1093-7.
  30. Morrow M (2011). Prophylactic mastectomy of the contralateral breast.Breast, 20, 108-10.
  31. Narod SA (2011). The impact of contralateral mastectomy on mortality in BRCA1 and BRCA2 mutation carriers with breast cancer. Breast Cancer Res Treat, 128, 581-3.
  32. Nichols HB, Berrington de Gonzalez A, et al (2011). Declining incidence of contralateral breast cancer in the United States from 1975 to 2006. J Clin Oncol, 29, 1564-9.
  33. Peralta EA, Ellenhorn JD, Wagman LD, et al (2000). Contralateral prophylactic mastectomy improves the outcome of selected patientsundergoing mastectomy for breast cancer. Am J Surg, 180, 439-45.
  34. Reiner AS, John EM, Brooks JD, et al (2013). Risk of asynchronous contralateral breast cancer in noncarriers of BRCA1 and BRCA2 mutations with a family history of breast cancer: a report from the Women's Environmental Cancer and Radiation Epidemiology Study. J Clin Oncol, 31, 433-9.
  35. Rosenberg SM, Tracy MS, Meyer ME, et al (2013). Perceptions, Knowledge, and Satisfaction With Contralateral Prophylactic Mastectomy Among Young Women With Breast Cancer: A Cross-sectional Survey. Ann Intern Med, 159, 373-81.
  36. Shavers VL, Harlan LC, Stevens JL (2003) Racial/ethnic variation in clinical presentation, treatment, and survival among breast cancer patients under age 35. Cancer, 97, 134-47.
  37. Silber JH, Rosenbaum PR, Clark AS, et al (2013). Characteristics associated with differences in survival among black and white women with breast cancer. JAMA, 310, 389-97.
  38. Society of Surgical Oncology (2013). Position Statement on Prophylactic Mastectomy Accessed September 24.
  39. Telli ML, Chang ET, Kurian AW, et al (2011) Asian ethnicity and breast cancer subtypes: a study from the California Cancer Registry. Breast Cancer Res Treat, 127, 471-8.
  40. Tuttle TM, Habermann EB, Grund EH, Morris TJ, Virnig B (2007). Increasing use of contralateral prophylactic mastectomy for breast cancer patients: a trend toward more aggressive surgical treatment. J Clin Oncol, 25, 5203-9.
  41. Tuttle TM, Jarosek S, Habermann EB, et al (2009). Increasing rates of contralateral prophylactic mastectomy among patients with ductal carcinoma in situ. J Clin Oncol, 27, 1362-7.
  42. van Sprundel TC, Schmidt MK, Rookus MA, et al (2005). Risk reduction of contralateral breast cancer and survival after contralateral prophylactic mastectomy in BRCA1 or BRCA2 mutation carriers. Br J Cancer, 93, 287-92.
  43. Yao K, Stewart AK, Winchester DJ, Winchester DP (2010). Trends in contralateral prophylactic mastectomy for unilateral cancer: a report from the National Cancer Data Base, 1998-2007. Ann Surg Oncol, 17, 2554-62.
  44. Yao K, Winchester DJ, Czechura T, Huo D (2013). Contralateral prophylactic mastectomy and survival: report from the National Cancer Data Base, 1998-2002. Breast Cancer Res Treat. [Epub ahead of print].
  45. Zendejas B, Moriarty JP, O'Byrne J, et al (2010) Costeffectiveness of contralateral prophylactic mastectomy versus routine surveillance in patients with unilateral breast cancer. J Clin Oncol, 29, 2993-3000.

Cited by

  1. Long-Term Survival of Women with Locally Advanced Breast Cancer with ≥10 Involved Lymph Nodes at Diagnosis vol.15, pp.8, 2014,
  2. Contralateral Breast Cancer: a Clinico-pathological Study of Second Primaries in Opposite Breasts after Treatment of Breast Malignancy vol.16, pp.3, 2015,
  3. Contralateral Risk-Reducing Mastectomy: Review of Risk Factors and Risk-Reducing Strategies vol.2015, pp.2090-1410, 2015,
  4. Evaluation of recurrence patterns and survival in modern series of young women with breast cancer vol.24, pp.5, 2018,